Chronic graft versus host disease
Not yet recruitingStudy of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy
Study of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy
- Disease:Chronic graft versus host disease
- Substances:BortezomibCarfilzomib+8
France- Participants:0–17 years · 18–64 years · 65+ years
- Substances:Bortezomib
- Sponsor:Sanofi-Aventis Recherche & Developpement










